Bridgebio Pharma SEC Filings

BridgeBio Pharma (BBIO) filed a Form 144 notifying a proposed sale of 26,156 common shares acquired as restricted stock units on 08/16/2025. The filing lists Morgan Stanley Smith Barney LLC as the broker and shows an aggregate market value of $1,279,289.96 for the proposed sale, with the shares to be sold on 08/20/2025 on NASDAQ. The securities to be sold were granted and acquired from the issuer on 08/16/2025 and paid on that date, identified as Restricted Stock Units. The filing also reports multiple prior Rule 10b5-1 sales during July and August 2025, each for 20,000 shares executed by related trusts, totaling eight reported transactions.

BridgeBio Pharma insider filing: Maricel Apuli, the company's Chief Accounting Officer, reported a transaction dated 08/16/2025 related to the vesting of restricted stock units. The filing shows 4,781 shares of common stock were withheld to satisfy tax obligations at a reported price of $51.32 per share following the vesting of 9,409 RSUs.

After the withholding, Ms. Apuli beneficially owns 137,078 shares of BridgeBio Pharma (BBIO) on a direct basis. The Form 4 is a routine disclosure of compensation-related share withholding and does not include derivative transactions or other purchases or sales.

BridgeBio Pharma insider filing: Thomas Trimarchi, the company’s President and Chief Financial Officer, reported transactions in the issuer’s common stock. On 08/16/2025, 21,317 shares were withheld to satisfy tax withholding related to the vesting of 38,547 restricted stock units, leaving the reporting person with 480,671 shares beneficially owned. On 08/18/2025, Trimarchi sold a total of 17,353 shares under a Rule 10b5-1 sales plan adopted March 31, 2025, at weighted average prices of $50.1437 and $50.9439, reducing beneficial ownership to 463,318 shares. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

BridgeBio Pharma director and CEO Neil Kumar reported transactions on 08/16/2025 showing vesting and tax-withholding activity tied to Restricted Stock Units (RSUs). A total of 64,697 RSU shares vested (reported as acquisition), and 32,855 shares were withheld to satisfy tax obligations at an indicated price of $51.32 per share. After these transactions the reporting person directly beneficially owned 282,101 shares and indirectly beneficially owned 4,718,447 and 915,686 shares through two trusts, of which he is co-trustee. Multiple tranches of RSUs continue to vest quarterly with no expiration.

BridgeBio Pharma (BBIO) Form 144 filing: The filing notifies a proposed sale of 17,353 shares of common stock through Morgan Stanley Smith Barney LLC on 08/18/2025 with an aggregate market value of $871,722.75. The filing reports 191,168,504 shares outstanding. The shares to be sold were issued as restricted stock in four grants: 4,757 shares acquired 11/16/2023, 3,048 shares acquired 08/16/2023, 6,264 shares acquired 02/16/2024, and 3,284 shares acquired 05/16/2024. The filer reports nothing to report for securities sold in the past three months and affirms they do not possess undisclosed material adverse information.

Amendment No. 8 to a Schedule 13D reports updated beneficial ownership information for the common stock of BridgeBio Pharma, Inc. ("Common Stock"). Multiple Viking-related entities and individuals are disclosed as reporting persons. Percentage calculations are based on 191,168,504 shares outstanding as of July 29, 2025. The cover pages show key positions: Viking Global Investors LP reports shared beneficial ownership of 17,780,183 shares (9.3%); Viking Global Opportunities-related entities report shared holdings of 17,489,651 shares (9.1%); and three individuals (O. Andreas Halvorsen, David C. Ott and Rose S. Shabet) are each reported with shared beneficial ownership of 18,602,920 shares (9.7%). The filing states the funds used were investor capital and incorporates a Schedule of Transactions as Exhibit 99.8. No transactions since Amendment No. 7 are reported except those listed in Exhibit 99.8.

BridgeBio Pharma director Charles J. Homcy executed pre-planned stock sales under a Rule 10b5-1 plan, selling a total of 300,000 shares of BBIO across transactions dated 08/08/2025 and 08/11/2025. The filings show sales of 191,662 shares at a weighted average price near $45.87, 58,338 shares at a weighted average near $46.64, and 50,000 shares at $48, leaving the reporting person with 916,674 shares following the final sale.

The disclosure notes the transactions were effected under a 10b5-1 plan adopted May 8, 2025, and the reporter remains a significant holder with well over nine hundred thousand shares. All sales are reported as direct holdings without derivative activity disclosed.

BridgeBio Pharma (BBIO) Form 4 filed by Maricel Apuli, Chief Accounting Officer, reports a sale on 08/07/2025 of 1,000 shares of common stock at $45.44 per share. After the transaction, Apuli directly beneficially owned 141,859 shares. The form was signed on 08/11/2025. No derivative transactions were reported.

BridgeBio Pharma CEO and director Kumar Neil reported the sale of common stock on August 7–8, 2025. The Form 4 discloses total dispositions of 217,404 shares, and notes the transactions were effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025.

Footnotes disclose weighted average sale price ranges of approximately $44.31–$47.20 per share across the transactions. The filing lists indirect beneficial ownership following the reported transactions, including holdings of 4,718,447 and 915,686 shares via two trusts, and is signed by an attorney-in-fact on August 11, 2025.